Meeting ID: 984 9062 5876
Dial by your location
+1 669 900 6833 US (San Jose)
+1 213 338 8477 US (Los Angeles)
Meeting ID: 984 9062 5876
Long Acting Injectable Cabotegravir for HIV Prevention: Expanding the PrEP Toolbox
Dr. Landovitz received his BA in Chemistry from Princeton University (Princeton, New Jersey, USA), and received his medical degree from Harvard Medical School (Boston, Massachusetts, USA). Following this, he completed an internship, residency, and served as Chief Resident in Internal Medicine at Brigham and Women’s Hospital (Boston, Massachusetts, USA) and an Infectious Diseases fellowship with Brigham and Women’s Hospital and Massachusetts General Hospital (Boston, Massachusetts, USA). He served as Medical Co-Director of the Vietnam-CDC-Harvard Medical School-AIDS-Partnership (VCHAP), helping to train Vietnamese physicians in HIV care and treatment. He is an infectious disease and HIV clinician and clinical investigator whose research interests include HIV prevention (including pre- and post-exposure prophylaxis and other combination prevention strategies) and the impact of such prevention interventions on risk behavior. Dr. Landovitz works with the United States National Institutes of Health (NIH)-funded Division of AIDS (DAIDS) clinical trials networks for HIV therapeutics and HIV Prevention. He is has led numerous clinical trials, and currently leads the NIH trials developing long-acting injectable cabotegravir for HIV prevention. In 2010, he was awarded the John Carey Young Investigator Award by the AIDS Clinical Trials Group in 2010, and the American Association of HIV Medicine Research Award in 2017. Dr. Landovitz is the Co-director of the UCLA Center for Clinical AIDS Research & Education (CARE) and of the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS).
Early Stage Investigator Speaker
PrEP uptake, engagement, and HIV incidence after population-level HIV testing in rural Kenya and Uganda: Findings from the SEARCH study
Catherine Koss, MD is an infectious disease physician and Assistant Professor in the Division of HIV, Infectious Diseases, and Global Medicine at San Francisco General Hospital (SFGH). Dr. Koss conducts clinical and implementation research on HIV prevention, with a major focus on developing strategies to optimize uptake of and adherence to pre-exposure prophylaxis (PrEP) among women in East Africa and the United States. She also has a major interest in adherence measurement for both HIV treatment and prevention. Dr. Koss is an attending physician on the HIV and Infectious Diseases consult service and a primary care provider at the Ward 86 HIV clinic at SFGH. In this talk, she will present findings from a population-based PrEP study in rural Kenya and Uganda on behalf of the Sustainable East Africa Research in Community Health (SEARCH) collaboration.